Recent Updates — LSTA
The board of directors approved an increase in size from seven to eight members and appointed Jeffrey Farrow as a Class III director effective October 13, 2026. Mr. Farrow joins the Audit Committee and brings extensive experience as CFO of multiple biopharmaceutical companies, including Tarsus Pharmaceuticals, Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics. He is classified as an independent director under Nasdaq listing rules. Lisata Therapeutics operates in the clinical-stage pharmaceutical industry, developing treatments for severe hypertriglyceridemia and acromegaly.
On September 17, 2026, Lisata Therapeutics completed its acquisition of Marea Therapeutics via a stock-for-stock merger. Former Marea shareholders received approximately 1.79 million shares of common stock and 211,365 shares of Series C Non-Voting Convertible Preferred Stock. Concurrently, Lisata raised $225 million in a private placement by issuing 150,868 shares of Series C Preferred Stock to institutional investors. Post-transaction ownership is projected at approximately 59.54% for former Marea equityholders and 38.07% for new investors. Ted W. Love was appointed to the Board, and Josh Lehrer became President and Chief Operating Officer. Lisata Therapeutics operates in the clinical-stage pharmaceutical industry.
Lisata Therapeutics announced a reduction in workforce by approximately 72%, effective immediately, to cut operating expenses while pursuing strategic options. The company estimates $1.2 million in severance and termination costs through the quarter ending September 30, 2026. Concurrently, Executive Vice President of R&D and Chief Medical Officer Dr. Kristen K. Buck was terminated without cause, entitling her to 12 months of base salary and target bonus plus COBRA premiums. Senior Vice President James Nisco received a $200,000 cash retention bonus payable if he remains employed through December 31, 2026. Additionally, the company filed a lawsuit in Delaware Court of Chancery against Kuva Labs Inc. for breach of merger agreement, seeking damages for expected stockholder benefits. Lisata Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.
Lisata Therapeutics, Inc. terminated its previously announced merger agreement with Kuva Labs Inc. and Kuva Acquisition Corp. due to the acquirer's failure to secure sufficient financing to fund the tender offer. As a result of the termination, the acquirer is obligated to pay a $2,000,000 termination fee to the Company. The Company's Board of Directors is now conducting a strategic review to explore business combinations, asset sales, or dissolution. Lisata Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic solutions for various medical conditions.
Lisata Therapeutics, Inc. entered into an amendment to its previously announced merger agreement with Kuva Labs Inc. and Kuva Acquisition Corp. to extend the outside date of the transaction from July 17, 2026, to July 21, 2026. Lisata Therapeutics, Inc. operates in the biopharmaceutical industry and develops therapeutic solutions for various medical conditions.
Lisata Therapeutics, Inc. entered into an amendment to its Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp. to extend the tender offer commencement date to June 10, 2026, and the Outside Date to July 17, 2026. The amendment includes a non-refundable $1,500,000 extension fee option for Parent to extend the deadline to August 17, 2026. Lisata agreed to waive certain claims against the acquirer, including a waived interim operating payment of $250,000, provided specific payments are made. Lisata Therapeutics, Inc. is a biopharmaceutical company focused on developing clinical-stage product candidates.